Skip To Main Content
Narendra Revansiddha Kale on Muck Rack

Narendra Revansiddha Kale

As seen in: ACS Publications, Royal Society of Chemistry
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Narendra Revansiddha

Contact Narendra Revansiddha, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Nanoparticles for Delivery of Encapsulated Drugs to Hypoxic Pancreatic Ductal Adenocarcinoma Cell Spheroids

|
By Narendra Revansiddha Kale, Chukwuebuka Ozoude, Connor Edvall, Shubhashri Ambhore
| dx.doi.org
Open in Who Shared Issue with article?

Metal-Organic Framework Induced Stabilization of Proteins in Polymeric Nanoparticles

|
By Zoe Armstrong, Mary Lenertz, Narendra Revansiddha Kale, Briana Saenz
| dx.doi.org
Download Hi-Res ImageDownload to MS-PowerPointCite This:ACS Appl. Mater. Interfaces 2024, XXXX, XXX Terms & Conditions Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses).
Open in Who Shared View Duplicates (700) Issue with article?

Antibody mediated cotton-archetypal substrate for enumeration of circulating tumor cells and chemotherapy outcome in 3D tumors

|
By Smriti Arora, Balram Singh, Narendra Revansiddha Kale, Bhagwat Jadhav
| Royal Society of Chemistry Verified
Antibody mediated cotton-archetypal substrate for enumeration of circulating tumor cells and chemotherapy outcome in 3D tumors Circulating tumor cells (CTCs) represent a distinct cancer biomarker established in clinical settings for early cancer detection, metastasis progression, and minimal residual disease (MRD) monitoring. Despite numerous advances, the comprehensive molecular characterization of CTCs is extremely challenging owing to their rarity and heterogeneity.
Open in Who Shared Issue with article?
See all 7 articles